EP2814498A4 - Compositions d'oligonucléotide riche en guanosine (gro), procédés et utilisations pour traiter une infection par le virus respiratoire syncytial - Google Patents

Compositions d'oligonucléotide riche en guanosine (gro), procédés et utilisations pour traiter une infection par le virus respiratoire syncytial

Info

Publication number
EP2814498A4
EP2814498A4 EP13758208.6A EP13758208A EP2814498A4 EP 2814498 A4 EP2814498 A4 EP 2814498A4 EP 13758208 A EP13758208 A EP 13758208A EP 2814498 A4 EP2814498 A4 EP 2814498A4
Authority
EP
European Patent Office
Prior art keywords
gro
guanosine
compositions
treating
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13758208.6A
Other languages
German (de)
English (en)
Other versions
EP2814498B1 (fr
EP2814498A1 (fr
Inventor
Richard George Hegele
Peter Mastrangelo
Theo Moraes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children
University of Toronto
Original Assignee
Hospital for Sick Children
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children, University of Toronto filed Critical Hospital for Sick Children
Publication of EP2814498A1 publication Critical patent/EP2814498A1/fr
Publication of EP2814498A4 publication Critical patent/EP2814498A4/fr
Application granted granted Critical
Publication of EP2814498B1 publication Critical patent/EP2814498B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP13758208.6A 2012-02-16 2013-02-15 Compositions d'oligonucléotide riche en guanosine (gro) et utilisations pour traiter une infection par le virus respiratoire syncytial Not-in-force EP2814498B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261599653P 2012-02-16 2012-02-16
PCT/CA2013/050123 WO2013131182A1 (fr) 2012-02-16 2013-02-15 Compositions d'oligonucléotide riche en guanosine (gro), procédés et utilisations pour traiter une infection par le virus respiratoire syncytial

Publications (3)

Publication Number Publication Date
EP2814498A1 EP2814498A1 (fr) 2014-12-24
EP2814498A4 true EP2814498A4 (fr) 2015-02-25
EP2814498B1 EP2814498B1 (fr) 2017-05-10

Family

ID=49115824

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13758208.6A Not-in-force EP2814498B1 (fr) 2012-02-16 2013-02-15 Compositions d'oligonucléotide riche en guanosine (gro) et utilisations pour traiter une infection par le virus respiratoire syncytial

Country Status (5)

Country Link
US (1) US9476049B2 (fr)
EP (1) EP2814498B1 (fr)
CN (1) CN104703608A (fr)
CA (1) CA2864766C (fr)
WO (1) WO2013131182A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180036427A1 (en) * 2015-03-04 2018-02-08 Inserm (Institut National De La Santé Etde La Rech Médicale) Methods and pharmaceutical compositions for the treatment of hiv infection
CN105296491B (zh) * 2015-11-27 2018-06-15 北京大学 一种经化学修饰后的核酸适配体as1411及其用途
CN114958860B (zh) * 2022-06-27 2023-07-28 华侨大学 呼吸道合胞病毒核酸适配体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061597A1 (fr) * 1999-04-08 2000-10-19 Uab Research Foundation Procede inhibant la proliferation d'oligonucleotides riches en guanosine et procede de liaison desdits oligonucleotides a la nucleoline
WO2005037323A2 (fr) * 2003-10-10 2005-04-28 University Of Louisville Research Foundation, Inc. Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284084A1 (fr) 1997-03-12 1998-09-17 Institut Pasteur Recepteur membranaire pour retrovirus de vih, utilisations therapeutiques et diagnostiques
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20040002457A1 (en) 2002-03-12 2004-01-01 Hovanessian Ara V. Inhibition of virus anchorage by RGG domain of a cell surface-expressed protein, polynucleotide coding for said RGG domain, therapeutic uses thereof by inhibition of microorganism or protein ligand binding to the cell-surface-expressed protein
US7807648B2 (en) * 2005-10-06 2010-10-05 University Of Delaware G-rich polynucleotides for the treatment of Huntington's Disease
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
JP2011511051A (ja) * 2008-02-05 2011-04-07 アンティソマ リサーチ リミテッド 生物学的物質およびそれらの使用
US8569252B2 (en) * 2009-04-15 2013-10-29 Postech Academy-Industry Foundation Nucleolin specific aptamer and use thereof
WO2011123945A1 (fr) 2010-04-06 2011-10-13 The University Of British Columbia Compositions, procédés et utilisations destinés au traitement d'une infection par un virus respiratoire syncytial
WO2011129495A1 (fr) 2010-04-16 2011-10-20 Kim Hyoung Jun Procédé d'extraction d'une substance anticarie à partir de réglisse
WO2011133142A1 (fr) * 2010-04-20 2011-10-27 University Of Louisville Traitement de tumeurs vhl négatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061597A1 (fr) * 1999-04-08 2000-10-19 Uab Research Foundation Procede inhibant la proliferation d'oligonucleotides riches en guanosine et procede de liaison desdits oligonucleotides a la nucleoline
WO2005037323A2 (fr) * 2003-10-10 2005-04-28 University Of Louisville Research Foundation, Inc. Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FARNOOSH TAYYARI ET AL: "Identification of nucleolin as a cellular receptor for human respiratory syncytial virus", NATURE MEDICINE, vol. 17, no. 9, 14 August 2011 (2011-08-14), pages 1132 - 1135, XP055161385, ISSN: 1078-8956, DOI: 10.1038/nm.2444 *
RICHARD G. HEGELE: "Making sense of cell surface nucleolin: Implications for respiratory syncytial virus prophylaxis and therapy", CELL CYCLE, vol. 11, no. 1, 1 January 2012 (2012-01-01), pages 1 - 2, XP055161379, ISSN: 1538-4101, DOI: 10.4161/cc.11.1.18466 *
See also references of WO2013131182A1 *

Also Published As

Publication number Publication date
WO2013131182A1 (fr) 2013-09-12
EP2814498B1 (fr) 2017-05-10
CA2864766A1 (fr) 2013-09-12
EP2814498A1 (fr) 2014-12-24
CN104703608A (zh) 2015-06-10
US20150010618A1 (en) 2015-01-08
CA2864766C (fr) 2017-09-05
US9476049B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
IL284578A (en) Double-stranded RNA suppressors of the hepatitis B virus, preparations containing them and their uses
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
EP2707540A4 (fr) Procédé de traitement d'une cellulose microfibrillée, et cellulose microfibrillée traitée selon le procédé
EP2720716A4 (fr) Compositions à base de levure, et procédés de traitement ou de prévention d'une infection par le virus delta de l'hépatite
EP2658857A4 (fr) Nucléosides puriques substitués, dérivés phosphoramidate et phosphorodiamidate pour le traitement d'infections virales
EP2785668A4 (fr) Compositions ionisées fluides, leurs procédés de préparation et leurs utilisations
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
EP2991679A4 (fr) Réactifs multispécificité, procédés de préparation et d'utilisation associés
EP2890403A4 (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et par le virus de l'hépatite d
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.
EP3049104A4 (fr) Compositions de vaccins, adjuvants et procédés pour le traitement d'infections urinaires
EP2897622A4 (fr) Procédés pour le traitement ou la prévention de dommages résultant d'un rayonnement, d'un trauma ou d'un choc
EP2729008A4 (fr) Systèmes, méthodes, et formulations pour traiter le cancer
EP2897689A4 (fr) Systèmes, compositions et procédés pour le traitement de l'alopécie
BR112014025339A8 (pt) método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo.
EP2753363A4 (fr) Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires
HRP20190393T1 (hr) Pripravak protutijela namijenjen sprječavanju ili liječenju infekcije mutantnim virusom hepatitisa b
LT2683245T (lt) Būdai ir kompozicijos, skirti depresijai gydyti panaudojant ciklobenzapriną
BR112014003556A2 (pt) método de tratamento de vírus, e, composição farmacêutica
EP2844258A4 (fr) Procédés et compositions pour traiter une infection bactérienne
IL236476A0 (en) Preparations and methods for the treatment or prevention of infection with the pneumovirus and diseases related to it
BR112014003003A2 (pt) compostos, respectivos usos e processos para tratar ou prevenir infecção viral

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140915

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20150123

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20150119BHEP

Ipc: A61K 31/711 20060101AFI20150119BHEP

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HOSPITAL FOR SICK CHILDREN

Owner name: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

17Q First examination report despatched

Effective date: 20160504

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602013020981

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031711000

Ipc: C12N0015115000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/115 20100101AFI20161115BHEP

Ipc: A61K 31/711 20060101ALI20161115BHEP

Ipc: A61P 31/14 20060101ALN20161115BHEP

INTG Intention to grant announced

Effective date: 20161207

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/711 20060101ALI20161128BHEP

Ipc: A61P 31/14 20060101ALN20161128BHEP

Ipc: C12N 15/115 20100101AFI20161128BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 892371

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170515

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013020981

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170510

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 892371

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170810

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170811

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170910

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170810

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013020981

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013020981

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180215

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180215

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180901

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180215

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510